Kowa Pharmaceuticals America, Inc.

Manufacturing inspections remain a sore spot for new drug and biologic applications, both because the COVID-19 pandemic still impeding the ability of inspectors to travel to facilities and because ins

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca To Study ‘Elite Controller’